Shiruyeh Schokrpur is an Oncology physician. OpenAlex indexes 58 publications with 2,094 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2279 45th St
Sacramento, CA 958171514
Telephone
916-734-5959Provider last certified this registry record 19 Apr 2024.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
51%Atypical Antipsychotic26%Olanzapine100%Part D<11 patientsPhenothiazine25%Prochlorperazine Maleate100%Part D≥14 patientsSensory organs
29.2%Corticosteroid29.2%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
19.8%Serotonin-3 Receptor Antagonist19.8%Ondansetron Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PP01.27: Real World Experience with Combination Chemotherapy-Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Journal of Thoracic Oncology
2026 - Activating the CXCR3/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinoma
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
npj Precision Oncology
2025 - Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity
Journal of Pharmacology and Experimental Therapeutics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”